Q-omics provides the consensus-scored LMOD1 profile across patient tissues and cancer cell-line models. LMOD1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, LMOD1 is differentially expressed in 16, with the highest sampling consensus in BLCA. Additionally, LMOD1 protein abundance shows 27,744 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRP, BLCA, and LSCC as cancer lineages where LMOD1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LMOD1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LMOD1 survival associations across molecular data types. LMOD1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LMOD1 RNA expression–survival associations across cancer types. High LMOD1 expression shows unfavorable associations in KIRP and BLCA, but favorable associations in LIHC, KIRC, ACC and CHOL. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for LMOD1 RNA expression.
This table summarizes LMOD1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 7. The strongest signals are observed in THCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for LMOD1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LMOD1 shows lower tumor expression in BLCA, THCA, KICH, COAD, LUAD and KIRP. The BLCA box plot shows higher LMOD1 RNA expression in normal versus tumor tissue (log2 FC = −6.475, t-test p < 0.001).
This table shows molecular features associated with LMOD1 in patient tissues and cancer cell lines. In patient samples, LMOD1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, LMOD1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and UPPER_AERODIGESTIVE_TRACT.
